Literature DB >> 23240094

Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients.

Frank Rauch1, Pierre Moffatt, Moira Cheung, Peter Roughley, Liljana Lalic, Allan M Lund, Norman Ramirez, Somayyeh Fahiminiya, Jacek Majewski, Francis H Glorieux.   

Abstract

BACKGROUND: Osteogenesis imperfecta (OI) type V is an autosomal dominant bone fragility disorder that we had described a decade ago. Recent research has shown that OI type V is caused by a recurrent c.-14C>T mutation in IFITM5. In the present study, we assessed all patients diagnosed with OI type V at our institutions for the presence of the IFITM5 mutation.
METHODS: IFITM5 exon 1 was analysed by Sanger sequencing in genomic DNA from 42 patients with OI type V (age: 2-67 years; 18 female).
RESULTS: The c.-14C>T mutation of IFITM5 was detected in all individuals. Indicators of disease severity varied widely: Height z-scores (n=38) ranged from -8.7 to -0.1, median -3.5. Median final height was 147 cm in men (N=15) and 145 cm in women (N=10). Lumbar spine areal bone mineral density z-scores in the absence of bisphosphonate treatment (n=29) were between -7.7 and -0.7, median -5.3. Scoliosis was present in 57%, vertebral compression fractures in 90% of patients.
CONCLUSIONS: Even though the disease-causing mutation is identical among patients with OI type V, the interindividual phenotypic variability is considerable.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23240094     DOI: 10.1136/jmedgenet-2012-101307

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  48 in total

Review 1.  Bone biology: insights from osteogenesis imperfecta and related rare fragility syndromes.

Authors:  Roberta Besio; Chi-Wing Chow; Francesca Tonelli; Joan C Marini; Antonella Forlino
Journal:  FEBS J       Date:  2019-07-05       Impact factor: 5.542

Review 2.  IFITM5 mutations and osteogenesis imperfecta.

Authors:  Nobutaka Hanagata
Journal:  J Bone Miner Metab       Date:  2015-06-02       Impact factor: 2.626

3.  A transgenic mouse model of OI type V supports a neomorphic mechanism of the IFITM5 mutation.

Authors:  Caressa D Lietman; Ronit Marom; Elda Munivez; Terry K Bertin; Ming-Ming Jiang; Yuqing Chen; Brian Dawson; Mary Ann Weis; David Eyre; Brendan Lee
Journal:  J Bone Miner Res       Date:  2015-03       Impact factor: 6.741

Review 4.  Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.

Authors:  P Trejo; F Rauch
Journal:  Osteoporos Int       Date:  2016-08-05       Impact factor: 4.507

5.  DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum.

Authors:  G Bardai; P Moffatt; F H Glorieux; F Rauch
Journal:  Osteoporos Int       Date:  2016-08-11       Impact factor: 4.507

6.  PHENOTYPIC VARIABILITY IN INDIVIDUALS WITH TYPE V OSTEOGENESIS IMPERFECTA WITH IDENTICAL IFITM5 MUTATIONS.

Authors:  Jamie Fitzgerald; Paul Holden; Hollis Wright; Beth Wilmot; Abigail Hata; Robert D Steiner; Don Basel
Journal:  J Rare Disord       Date:  2013-12

7.  Type V osteogenesis imperfecta undergoing surgical correction for scoliosis.

Authors:  Morgan Jones; Lee Breakwell; Ashley Cole; Paul Arundel; Nick Bishop
Journal:  Eur Spine J       Date:  2018-02-19       Impact factor: 3.134

8.  Contemporary Approaches for Identifying Rare Bone Disease Causing Genes.

Authors:  Charles R Farber; Thomas L Clemens
Journal:  Bone Res       Date:  2013       Impact factor: 13.567

9.  Regulation of the bone-restricted IFITM-like (Bril) gene transcription by Sp and Gli family members and CpG methylation.

Authors:  Bahar Kasaai; Marie-Hélène Gaumond; Pierre Moffatt
Journal:  J Biol Chem       Date:  2013-03-24       Impact factor: 5.157

10.  Osteogenesis imperfecta without features of type V caused by a mutation in the IFITM5 gene.

Authors:  Monica Grover; Philippe M Campeau; Caressa Dee Lietman; James T Lu; Richard A Gibbs; Alan E Schlesinger; Brendan H Lee
Journal:  J Bone Miner Res       Date:  2013-11       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.